RE: Quite promising27 Apr 2020 19:44
Thus, nebulized IFN-ß treatment is the first therapy acting on the causal viral pathway that seems able to prevent worsening of asthma symptoms if administered shortly after patients become aware of a cold developing
Additionally, IFN-ß treatment resulted in a modest, but significant, induction of systemic innate immune responses as judged by the genome-wide gene expression analysis of blood cells, which showed significant differences in genes involved in type I IFN signaling. Together with the sustained and marked elevation of CXCL10 protein levels in blood, this suggests that treatment with IFN-ß enhanced innate immunity, which in turn improved the clinical outcome of the cold. The trend toward reduced load of RV in sputum observed with treatment suggests that better antiviral defenses may result in faster clearance of RVs. Further studies, including analysis of other viruses, are required for more definitive proof.
In summary, this study suggests for the first time that administration of IFN-ß by inhalation can enhance innate immunity both locally within the lungs and, to a lesser extent, systemically, thereby compensating for the IFN-ß deficiency that we have previously demonstrated ex vivo in the epithelium of patients with moderate-severe asthma (6). The possible beneficial clinical effect of treatment seen in patients with moderate-severe asthma that was associated with this enhancement suggests that this treatment may impact favorably on cold-induced asthma exacerbations. The trial was designed and powered on the basis of the entire mITT patient population; therefore, further adequately powered studies focusing on more difficult-to-treat people with asthma are now needed to test the hypothesis that IFN-ß is effective in this high-risk patient population
GLA
Sign In
Follow the stocks
